CTI BioPharma Announces Publication Of Phase 2 Results Of Pacritinib

(RTTNews) - CTI BioPharma Corp. (CTIC) announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

Results of the Phase 2 study demonstrated that pacritinib is active in patients with myelofibrosis, resulting in spleen volume reduction, while producing substantial and prolonged improvement in disease-related symptoms without causing clinically significant myelosuppression.

The company believed pacritinib was well tolerated, including in patients with disease-related anemia and thrombocytopenia, with the predominant side effect being manageable gastrointestinal toxicity.

"Based on the results of this study and the recently announced PERSIST-1 top-line data, we believe pacritinib may provide an important therapeutic option for a broader spectrum of patients suffering from this challenging disease. We look forward to presenting additional data from PERSIST-1 at a scientific conference this year," said James A. Bianco, M.D., President and CEO of CTI BioPharma.

Myelofibrosis is one of three main types of myeloproliferative neoplasms (MPNs), which are a closely related group of hematological blood cancers.